| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5702333 | Surgical Oncology | 2017 | 5 Pages |
Abstract
Complete response to neoadjuvant therapy has a significantly better overall and 3-year-survival after esophagectomy than incomplete response. In incomplete responders, residual lymph node disease was associated with a significantly worse survival. These findings suggest that the degree of pathologic response and lymph node status are major prognostic factors for survival in EAC patients with stage III disease.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Katrin Schwameis, Joerg Zehetner, Jeffrey A. Hagen, Daniel S. Oh, Stephanie G. Worrell, Kais Rona, Nathan Cheng, Jamil Samaan, Kyle M. Green, John C. Lipham,